当前位置: 首页 >> 检索结果
661. Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD.
作者: Frank G Holz.;Yannick Le Mer.;Mahiul M K Muqit.;Lars-Olof Hattenbach.;Andrea Cusumano.;Salvatore Grisanti.;Laurent Kodjikian.;Marco Andrea Pileri.;Frederic Matonti.;Eric Souied.;Boris V Stanzel.;Peter Szurman.;Michel Weber.;Karl Ulrich Bartz-Schmidt.;Nicole Eter.;Marie Noelle Delyfer.;Jean François Girmens.;Koen A van Overdam.;Armin Wolf.;Ralf Hornig.;Martina Corazzol.;Frank Brodie.;Lisa Olmos de Koo.;Daniel Palanker.;José-Alain Sahel.
来源: N Engl J Med. 2026年394卷3期232-242页
Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in such persons currently exist. The photovoltaic retina implant microarray (PRIMA) system combines a subretinal photovoltaic implant and glasses that project near-infrared light to the implant in order to restore sight to areas of central retinal atrophy.
662. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
作者: Neal D Shore.;Murilo de Almeida Luz.;Ugo De Giorgi.;Martin Gleave.;Geoffrey T Gotto.;Christopher M Pieczonka.;Gabriel P Haas.;Choung-Soo Kim.;Miguel Ramirez-Backhaus.;Antti Rannikko.;Matko Kalac.;Swetha Sridharan.;Matt Rosales.;Yiyun Tang.;Ronald F Tutrone.;Balaji Venugopal.;Arnauld Villers.;Henry H Woo.;Fong Wang.;Stephen J Freedland.
来源: N Engl J Med. 2026年394卷6期563-575页
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically recurrent prostate cancer. The final analysis of overall survival has not been reported.
663. Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
作者: Paolo A Ascierto.;Michele Del Vecchio.;Barbara Merelli.;Helen Gogas.;Ana M Arance.;Stéphane Dalle.;Charles Lance Cowey.;Michael Schenker.;Caroline Gaudy-Marqueste.;Jacopo Pigozzo.;Iván Márquez-Rodas.;Marcus O Butler.;Anna Maria Di Giacomo.;Oleg Gligich.;Luis De La Cruz-Merino.;Petr Arenberger.;Victoria Atkinson.;Paul Nathan.;Andrew Hill.;Michael Millward.;Leslie A Fecher.;Nikhil I Khushalani.;Paola Queirolo.;Raheela Soomro.;Dhanrajsinh Rathod.;Margarita Askelson.;Melanie Pe Benito.;Devanand Joseph.;James Larkin.
来源: N Engl J Med. 2026年394卷4期333-342页
In the CheckMate 238 trial, patients with resected stage IIIB-C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were needed on longer-term survival.
669. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
作者: Pasi A Jänne.;David Planchard.;Kunihiko Kobayashi.;James Chih-Hsin Yang.;Ying Liu.;Natalia Valdiviezo.;Tae Min Kim.;Liyan Jiang.;Hiroshi Kagamu.;Noriko Yanagitani.;Jialei Wang.;Bivas Biswas.;Artem Poltoratskiy.;Yeni Neron.;Carlos Rojas.;Leona Koubkova.;Carles Escriu.;Doreen A Ezeife.;Helen Mann.;Elena Armenteros-Monterroso.;Yuri Rukazenkov.;Chee Khoon Lee.; .
来源: N Engl J Med. 2026年394卷1期27-38页
The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). Results from the planned final analysis of overall survival are needed.
670. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
作者: Xiuning Le.;Tae Min Kim.;Herbert H Loong.;Arsela Prelaj.;Boon Cher Goh.;Lin Li.;Yong Fang.;Shun Lu.;Xiaorong Dong.;Lin Wu.;Yuki Shinno.;Gennaro Daniele.;Tsung-Ying Yang.;Hye Ryun Kim.;Gerrina Ruiter.;Jun Zhao.;Silvia Novello.;Liyun Miao.;Pasi A Jänne.;Koichi Goto.;Dominik Rüttinger.;Tine Descamps.;Jan Christoph Brase.;Weichao Bao.;Rui Li.;Nicoletta Brega.;Paolo Grassi.;Nicolas Girard.;Daniel Shao-Weng Tan.; .
来源: N Engl J Med. 2025年393卷18期1819-1832页
HER2 gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models.
678. BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.
作者: Laura Bucci.;Sebastian Böltz.;Melanie Hagen.;Carlo Tur.;Danae-Mona Nöthling.;Tobias Rothe.;Andreas Wirsching.;Janina Auth.;Jochen Wacker.;Markus Eckstein.;Stefano Alivernini.;Aline Bozec.;Christina Bergmann.;Maria-Antonietta D'Agostino.;Luis Munoz.;Jürgen Rech.;Lars Kihm.;Maria Gabriella Raimondo.;Georg Schett.;Ricardo Grieshaber-Bouyer.
来源: N Engl J Med. 2025年393卷15期1544-1547页 |